Skip to content


Correcting dysfunctional immune responses

Autoimmune diseases are characterized by an inappropriate immune system response that turns against the patient’s own tissues or organs. They affect approximately 5 to 8% of the world’s population1.

They are caused by multiple factors, which differ from one patient to the next, despite them all suffering from the same disease. It has become a challenge for the pharmaceutical industry to make innovative therapeutic solutions available to patients.

At Servier, we develop targeted therapies to correct the inappropriate immune response through different approaches such as:

  • targeting a protein that plays a role in the pathology.
  • targeting various adaptive immune system mechanisms, which could stop the production of auto-antibodies that drive disease.

Developing targeted therapeutic solutions

We focus our research on therapeutic solutions that offer a targeted approach on the pathological mechanisms that cause autoimmune diseases, especially monoclonal antibodies, which are therapeutic antibodies that have been specifically selected and engineered to bind and modify the activity of targets known to be involved in the disease.

Photo of two researchers

As part of the recent evolution of precision medicine approaches in drug discovery and development, antisense oligonucleotides (ASOs) have shown promise to revolutionize the treatment of particularly rare and genetically driven or inherited disease.

Learn more about our immuno-inflammation development projects

Got a question?

Want to report a side effect?
Check out our Pharmacovigilance page.

[1] World Health Organization